...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: share value/little perspective

Golf, MRNA's market cap is $160B (404 million share O/S x $396/sh). Your point is well taken although management would probably hint they are in a blackout as an excuse as to not putting their own money into this. Certainly many new investors would pass. Actually looking at RVX they would see a complete lack of qualified people in management (especially CEO), the seeming inability to get "a small inexpensive trial" off the ground despite months and months of hints that it's just about to start, no visibility on a follow up to BoM, and a complete lack of visible financial runway. The occasional burst of empty words with no follow through, in short a gong show.

The association with Eversana is a strong vote on the science and its commercial potential wrt covid, but looking at what covid did for Moderna probably makes many potential investors think that there is so much potential upside that they can right now just wait and see if RVX is able to get a trial launched and further see if it is successful. 

Share
New Message
Please login to post a reply